Corticosteroids regulate epithelial cell differentiation and Hassall body formation in the human thymus.
The presence of characteristic epithelial swirls called Hassall bodies within the human thymic medulla has been used as an indicator of ongoing or recent thymopoiesis. We present a case where Hassall bodies were present in the absence of current or past thymopoiesis. The patient had been treated with corticosteroids for presumed asthma before his diagnosis of X-linked SCID. Two other cases of nonimmunodeficient patients treated with high-dose corticosteroids had markedly increased numbers of thymic Hassall bodies. To determine whether corticosteroid treatment induces thymic epithelial (TE) differentiation to form Hassall bodies, mAbs reactive with specific cytokeratins (CKs), filaggrin, and involucrin were used to define distinct stages of TE cell differentiation. Treatment of primary TE monolayers with hydrocortisone in vitro induced expression of involucrin and high-molecular-mass CKs that are characteristic of TE differentiation. Treatment of thymic organ cultures with hydrocortisone induced both medullary and subcapsular cortical TE cells to express CK6, a differentiation marker that is normally expressed only by Hassall bodies in vivo. These experimental studies combined with the case observations indicate that exogenous corticosteroids can regulate terminal differentiation of TE cells both in vitro and in vivo. Thus, the presence of Hassall bodies in thymus from corticosteroid-treated patients cannot be taken as an absolute indication of previous thymopoiesis. Because corticosteroids are also made within the thymus under normal physiologic conditions, these studies support the hypothesis that endogenous corticosteroids may play a role in normal TE differentiation and Hassall body formation in vivo.
Hale
Laura P
LP
Department of Pathology, Duke University Medical Center, DUMC 3712, Durham, NC 27710, USA. laura.hale@duke.edu
Markert
M Louise
ML
D000305:Adrenal Cortex Hormones / Q000494:pharmacology* / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000032:analysis; D002454:Cell Differentiation / Q000187:drug effects; D041321:Chromosomes, Human, X / Q000235:genetics; D004847:Epithelial Cells / Q000166:cytology* / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D005260:Female; D000091344:Filaggrin Proteins; D006801:Humans; D006854:Hydrocortisone / Q000494:pharmacology; D016130:Immunophenotyping; D007223:Infant; D007231:Infant, Newborn; D007381:Intermediate Filament Proteins / Q000032:analysis / Q000276:immunology; D007633:Keratins / Q000032:analysis / Q000096:biosynthesis; D038041:Lymphopoiesis / Q000187:drug effects; D008297:Male; D009924:Organ Culture Techniques; D011498:Protein Precursors / Q000032:analysis / Q000096:biosynthesis; D016511:Severe Combined Immunodeficiency / Q000188:drug therapy / Q000235:genetics / Q000473:pathology; D013601:T-Lymphocytes / Q000276:immunology / Q000473:pathology; D013950:Thymus Gland / Q000166:cytology* / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology
D000305:Adrenal Cortex Hormones; D000911:Antibodies, Monoclonal; C000717249:FLG protein, human; D000091344:Filaggrin Proteins; D007381:Intermediate Filament Proteins; D011498:Protein Precursors; C032253:involucrin; D007633:Keratins; D006854:Hydrocortisone